[Antidepressants and pain].
A balanced inhibition of both serotonin and norepinephrine reuptake is usually evoked to explain the analgesic action of tricyclic and SNRI antidepressants but other mechanisms able to modulate the chronic pain-induced neuroplasticity may occur. Fundamental and clinical experiments are necessary to confirm the traditional monoaminergic hypothesis, to improve the efficacy of SRI and to better define the criteria of choice of antidepressants. These could open on novel therapeutic approaches for the management of chronic neuropathic pains as, for example the medication combination.
Eschalier
Alain
A
INSERM, U766, Faculté de médecine, Université d'Auvergne, 63001 Clermont-Ferrand, France.
Courteix
Christine
C
D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use; D000700:Analgesics / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000627:therapeutic use*; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D006801:Humans; D009437:Neuralgia / Q000188:drug therapy; D009473:Neuronal Plasticity / Q000187:drug effects; D010146:Pain / Q000188:drug therapy*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use
D018759:Adrenergic Uptake Inhibitors; D000700:Analgesics; D000928:Antidepressive Agents; D000929:Antidepressive Agents, Tricyclic; D017367:Selective Serotonin Reuptake Inhibitors